Menu
ÚHKT

Mgr. Martin Vostrý

odborný pracovník v laboratorních metodách

Tel: +420 221 977 306
Email: Martin.Vostry@uhkt.cz

Pracoviště:

Impaktované publikace

[1]

Votavova, H.; Urbanova, Z.; Kundrat, D.; Dostalova Merkerova, M.; Vostry, M.; Hruba, M.; Cermak, J.; Belickova, M.

Modulation of the immune response by deferasirox in myelodysplastic syndrome patients

[rok vydání 2021, impact factor 5.863 ]

[2]

Hájková, H.; Fritz, M.H-Y.; Haškovec, C.; Schwarz, J.; Šálek, C.; Marková, J.; Krejčík, Z.; Dostálová Merkerová, M.; Kostečka, A.; Vostrý, M.; Fuchs, O.; Michalová, K.; Cetkovský, P.; Beneš, V.

CBFB - MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

[rok vydání 2014, impact factor 4.812 ]

[3]

Skála, V.; Černíková, A.; Jindrová, Z.; Kašný, M.; Vostrý, M.; Walker, A.J.; Horák, P.

Influence of Trichobilharzia regenti (Digenea: Schistosomatidae) on the defence activity of Radix lagotis (Lymnaeidae) haemocytes

[rok vydání 2014, impact factor 3.234 ]

[4]

Jonasova, A.; Bokorova, R.; Polak, J.; Vostry, M.; Kostecka, A.; Hajkova, H.; Neuwirtova, R.; Siskova, M.; Sponerova, D.; Cermak, J.; Mikulenkova, D.; Cervinek, L.; Brezinova, J.; Michalova, K.; Fuchs, O.

High level of full length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

[rok vydání 2014, impact factor 2.544 ]

[5]

Neuwirtova, R.; Fuchs, O.; Holicka, M.; Vostry, M.; Kostecka, A.; Hajkova, H.; Jonasova, A.; Cermak, J.; Cmejla, R.; Pospisilova, D.; Belickova, M.; Siskova, M.; Hochova, I.; Vondrakova, J.; Sponerova, D.; Kadlckova, E.; Novakova, L.; Brezinova, J.; Michalova, K.

Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia

[rok vydání 2012, impact factor 2.396 ]

Neimpaktované publikace

[1]

Bokorova, R.; Polak, J.; Vostry, M.; Kostecka, A.; Fuchs, O.

Cereblon as the cellular target responsible for the anti-multiple myeloma activity of immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide)

[rok vydání 2014]